Key Highlights

  • CSL Limited reported an FY26 statutory net loss of USD 2.6 billion following substantial impairments.
  • Underlying NPATA declined 2% to USD 3.1 billion, while Operating Cash Flow reached USD 3.5 billion.
  • CSL expects approximately 5% underlying net profit growth during FY27 despite Vifor Revenue pressure.
  • Deborah Waterhouse will become Chief Executive Officer in February 2027, supporting the Leadership transition.

CSL Limited (ASX:CSL), an Australian-headquartered global biotechnology company specialising in plasma-derived therapies, influenza vaccines and treatments for serious medical conditions, is progressing a Business transformation following a challenging FY26 financial year. The company recorded a statutory net loss attributable to shareholders of approximately USD 2.6 billion, primarily reflecting substantial asset impairments and restructuring expenses. However, its underlying Earnings and operating cash flow remained positive, providing financial support for ongoing Investment in its therapeutic portfolio, Manufacturing infrastructure and operational efficiency initiatives.

The company's FY26 financial results, released on 18 August 2026, included approximately USD 7.1 billion in pre-tax Impairment and related charges and USD 799 million in restructuring expenses.

These charges reflected revised commercial expectations for selected products, increasing competition, regulatory developments and changes in manufacturing capacity assumptions.

Excluding significant non-recurring items and acquired intellectual property amortisation, underlying net profit after tax and before Amortisation (NPATA) attributable to CSL shareholders reached approximately USD 3.1 billion, representing a 2% decline in constant currency terms.

Despite these challenges, management expects underlying net profit after tax to increase by approximately 5% during FY27, supported by growth in CSL Behring and operational transformation initiatives.

The company has also announced the appointment of Deborah Waterhouse as its next Chief Executive Officer and Managing Director, effective 1 February 2027.

Understanding CSL's Global Biotechnology Business

CSL operates through three principal businesses: CSL Behring, CSL Seqirus and CSL Vifor.

These divisions develop, manufacture and commercialise treatments for patients with rare diseases, blood disorders, immune deficiencies and other serious medical conditions.

CSL Behring represents the company's largest business and specialises in plasma-derived and recombinant therapies.

Its products include immunoglobulins, albumin, haemophilia treatments and medicines for hereditary angioedema and other rare conditions.

Plasma-derived therapies are produced using plasma collected from donors through specialised collection centres.

The plasma undergoes processing and purification at manufacturing facilities before being converted into medicines used by hospitals and healthcare providers.

CSL Seqirus focuses on influenza Vaccine development, manufacturing and distribution.

The business supplies seasonal influenza vaccines and maintains capabilities associated with Pandemic preparedness.

CSL Vifor develops and commercialises treatments for iron deficiency, kidney disease and related medical conditions.

The company's revenue is generated through pharmaceutical product sales, licensing arrangements and other healthcare-related activities.

Its financial performance depends on product demand, manufacturing efficiency, regulatory approvals, reimbursement arrangements and competition from alternative therapies.

FY26 Financial Results Reflect Substantial Impairment Charges

For the financial year ended 30 June 2026, CSL reported total Operating Revenue of USD 15,797 million, compared with USD 15,558 million in FY25.

On a reported currency basis, revenue increased by approximately 1.5%. However, revenue declined by approximately 1% in constant currency terms, reflecting softer underlying trading conditions.

The company recorded a statutory net loss attributable to CSL shareholders of USD 2,579 million, compared with a net profit of USD 3,002 million in FY25.

The reduction primarily reflected restructuring expenses and non-cash impairment charges.

Pre-tax impairment and related charges reached approximately USD 7.1 billion during FY26, including USD 5.5 billion recognised in the second half.

Additional restructuring expenses totalled approximately USD 799 million.

These expenses reflected changes in the expected future performance of selected Assets and the company's operational transformation programme.

However, CSL's underlying financial measures presented a different picture.

Underlying NPATA attributable to shareholders reached USD 3,098 million, compared with USD 3,219 million in FY25.

This represented a decline of approximately 3.8% on a reported currency basis and 2% in constant currency terms.

Underlying net profit after tax, excluding acquired intellectual property amortisation, was USD 2,837 million attributable to shareholders, compared with USD 2,972 million in FY25.

The results highlight the distinction between recurring operating profitability and the accounting effects of asset impairments and restructuring.

Impairment Charges Reflect Revised Commercial Expectations

The impairment charges recognised during FY26 represented one of the most significant developments in CSL's financial results.

The company recorded approximately USD 7.1 billion in pre-tax impairment and related expenses.

These charges reflected revised assumptions regarding future product revenue, the timing of generic competition, regulatory conditions and manufacturing capacity utilisation.

An impairment occurs when the carrying value of an asset exceeds its estimated recoverable amount.

In such circumstances, the company recognises an accounting charge to reduce the asset's reported value.

Although impairment charges can substantially affect statutory earnings, they do not necessarily involve an equivalent cash payment during the reporting period.

CSL's impairment assessment included assets associated with its CSL Vifor business.

The company recognised a USD 1.7 billion impairment against Goodwill allocated to CSL Vifor.

This reflected lower projected future cash flows and changes in the commercial outlook for selected products.

Other impairment charges related to product assets, manufacturing facilities and contractual commitments.

The company also reviewed the expected utilisation of certain manufacturing assets.

These adjustments were influenced by changes in Demand assumptions, market competition and the future financial contribution expected from individual facilities.

The impairments reflect a reassessment of the value of selected assets, while CSL continues operating its core biotechnology businesses.

CSL Behring Remains the Largest Revenue Contributor

CSL Behring generated revenue of approximately USD 11,387 million during FY26, compared with USD 11,158 million in FY25.

Although reported revenue increased, the division recorded a decline of approximately 1% in constant currency terms.

The business continues providing plasma-derived and recombinant therapies for patients with immune deficiencies, bleeding disorders and other serious medical conditions.

Immunoglobulin products remain its largest therapeutic category.

These medicines are used to treat a range of immune-related and neurological conditions.

CSL Behring also produces albumin, haemophilia treatments and medicines for hereditary angioedema.

The division's FY26 performance was influenced by changes in product demand, inventory management and reimbursement arrangements.

However, newer therapies, including ANDEMBRY and HEMGENIX, contributed to revenue development.

The company continues focusing on plasma collection efficiency, manufacturing productivity and targeted investment in commercial capabilities.

These initiatives are intended to support the division's growth while improving operational efficiency.

Immunoglobulin Sales Reach USD 6.2 Billion

Immunoglobulin remained CSL Behring's largest revenue contributor during FY26.

Sales reached approximately USD 6.2 billion, broadly unchanged in constant currency terms compared with FY25.

The performance reflected several factors affecting the US market.

These included the company's decision to normalise immunoglobulin inventory levels across distribution channels, changes associated with Medicare Part D and the effects of previous tender losses.

Inventory normalisation can affect reported sales when distributors and other customers adjust stock levels to align with expected demand.

Consequently, product shipments may differ from underlying patient demand during particular reporting periods.

CSL continues investing in plasma collection and manufacturing capabilities to support its immunoglobulin business.

The company expects immunoglobulin revenue growth to improve during FY27.

Management has guided for mid-to-high single-digit growth in immunoglobulin sales, in line with its expectations for the broader market.

However, achieving this outlook will depend on patient demand, product availability, reimbursement conditions and competitive developments.

Albumin Sales Decline Following Changes in China

Albumin revenue declined during FY26, reflecting changing market conditions in China.

CSL reported albumin sales of approximately USD 1.1 billion, representing a 17% decline in constant currency terms.

The reduction was primarily attributed to government cost-containment measures affecting healthcare expenditure in China.

Albumin is a plasma-derived protein used in several medical settings, including the treatment of selected conditions involving low blood Volume or protein deficiency.

Demand can be influenced by hospital treatment practices, reimbursement arrangements and healthcare policies.

Changes in procurement requirements and pricing structures can therefore affect revenue.

For CSL, the lower albumin contribution reduced earnings within CSL Behring.

The company continues monitoring healthcare policy developments and customer demand across its international markets.

Future performance will depend on regulatory arrangements, pricing conditions and changes in hospital purchasing activity.

Newer Therapies Contribute to CSL Behring's Product Portfolio

CSL continues expanding its portfolio of treatments for rare and serious medical conditions.

During FY26, HEMGENIX recorded revenue growth of approximately 25% in constant currency terms.

HEMGENIX is a gene therapy developed for eligible adults with haemophilia B.

The treatment is intended to address the underlying deficiency in clotting Factor IX, reducing the need for certain ongoing replacement therapies in suitable patients.

Commercial adoption depends on patient eligibility, treatment centre capacity and reimbursement arrangements.

Meanwhile, ANDEMBRY generated approximately USD 240 million in sales during its first full year on the market.

ANDEMBRY is used for the prevention of hereditary angioedema attacks in eligible patients.

Hereditary angioedema is a rare condition characterised by recurring episodes of swelling.

The product's first full year of commercial availability contributed to growth within CSL's hereditary angioedema portfolio.

However, other products experienced pricing pressure.

KCENTRA revenue declined by approximately 17% in constant currency terms, reflecting competitive pricing conditions in the United States.

These contrasting trends demonstrate the importance of product Diversification and continued investment in new treatments.

CSL Vifor Faces Generic Competition and Regulatory Challenges

CSL Vifor generated approximately USD 2,379 million in revenue during FY26, compared with USD 2,234 million in FY25.

The division recorded growth of approximately 3% in constant currency terms.

The improvement was supported by selected nephrology products, partly offset by lower revenue from iron therapies.

Generic competition has become an increasingly important consideration for CSL Vifor.

Generic medicines can reduce revenue from established pharmaceutical products by introducing lower-priced alternatives after relevant exclusivity protections expire.

The company is also managing changes affecting VELPHORO, a treatment used in patients with chronic kidney disease.

The conclusion of a US reimbursement period for VELPHORO has influenced its commercial outlook.

Another development involved TAVNEOS, a medicine used in the treatment of certain inflammatory conditions.

Regulatory changes affecting its Marketing authorisation have reduced the expected future contribution from the product.

These factors contributed to the reassessment of CSL Vifor's asset values during FY26.

Looking ahead, CSL expects Vifor revenue to decline by approximately 25% during FY27.

The forecast incorporates generic competition, reimbursement changes and the regulatory developments affecting TAVNEOS.

CSL Seqirus Revenue Declines Despite Seasonal Influenza Growth

CSL Seqirus reported revenue of approximately USD 2,031 million during FY26, compared with USD 2,166 million in FY25.

This represented a decline of approximately 8% in constant currency terms.

The reduction primarily reflected the absence of non-recurring avian influenza-related revenue recorded in the preceding financial year.

However, the seasonal influenza vaccine business recorded growth.

Global seasonal influenza vaccine revenue increased by approximately 4% in constant currency terms.

The improvement occurred despite lower influenza vaccination rates in the United States.

CSL Seqirus supplies influenza vaccines across several international markets.

Its product portfolio includes FLUAD and FLUCELVAX.

FLUAD generated revenue of approximately USD 968 million, increasing by 5% in constant currency terms.

The increase reflected activity across multiple markets, including product launches in Germany and France.

FLUCELVAX generated revenue of approximately USD 503 million, also recording 5% growth.

The product benefited from activity in the US paediatric vaccination market.

These developments contributed to seasonal influenza revenue growth despite the decline in total Seqirus revenue.

Influenza Vaccination Trends Remain Important to Seqirus

CSL Seqirus operates in a market influenced by seasonal disease patterns, public health recommendations and government vaccination programmes.

Influenza vaccine demand varies between countries and seasons.

Immunisation rates can change because of public health campaigns, access to healthcare services and individual vaccination decisions.

In the United States, lower vaccination rates have influenced demand across the influenza vaccine market.

CSL expects this pressure to continue during FY27, although the rate of decline is anticipated to moderate.

The company has guided for low-single-digit revenue growth within Seqirus during FY27.

Its strategy includes continued investment in differentiated vaccine products and manufacturing efficiency.

CSL also maintains capabilities associated with pandemic preparedness and influenza vaccine development.

However, the business remains exposed to changes in vaccination demand, public health policies and competitive pricing.

The company previously postponed plans to separate CSL Seqirus into an independently listed business.

The decision reflected changing market conditions and uncertainty surrounding influenza vaccine demand.

No revised separation timetable has been established.

Transformation Programme Delivers USD 176 Million in Cost Savings

CSL continues implementing a group-wide transformation programme designed to simplify operations and improve expenditure efficiency.

The programme focuses on reducing organisational complexity, improving manufacturing productivity and aligning resources with business priorities.

During FY26, CSL achieved approximately USD 176 million in cost savings.

This exceeded the company's original target for the financial year.

The savings reflected changes to fixed infrastructure, operating processes and organisational arrangements.

CSL also progressed the integration of selected commercial and medical affairs activities across Behring and Vifor.

Combining these functions is intended to reduce duplication and improve coordination.

The company continues assessing opportunities to improve plasma collection efficiency and manufacturing operations.

However, restructuring requires upfront expenditure.

CSL recognised approximately USD 799 million in pre-tax restructuring expenses during FY26.

Some cost savings are also being reinvested into commercial operations and research programmes.

The eventual financial contribution will depend on the pace of implementation and the company's ability to maintain product availability and service standards.

Plasma Collection and Manufacturing Investment Supports Future Capacity

CSL continues investing in its plasma collection and manufacturing infrastructure.

The company has outlined plans to invest approximately USD 1.5 billion in expanding its US plasma manufacturing presence.

The investment includes manufacturing capacity improvements and the Horizon 2 Yield optimisation programme.

Plasma processing involves several stages, including collection, testing, purification and fractionation.

Manufacturing efficiency is important because the process requires specialised facilities and regulatory compliance.

Improving yields can increase the amount of therapeutic product obtained from available plasma.

However, manufacturing changes require technical validation and relevant regulatory approvals.

CSL is progressing clinical evidence requirements associated with Horizon 2 following engagement with regulatory authorities.

The programme is intended to improve plasma manufacturing productivity over time.

The company continues balancing these investments with cost management and the expected demand for its plasma-derived medicines.

Research and Development Remains a Business Priority

CSL maintains Research and Development activities across its therapeutic portfolio.

These include programmes involving rare diseases, blood disorders, immunology, nephrology and vaccines.

During FY26, the company entered into a strategic collaboration with biotechnology company VarmX.

The collaboration focuses on a potential treatment intended to restore blood coagulation in selected medical settings.

CSL continues evaluating development programmes according to clinical progress, commercial potential and regulatory requirements.

Research activities can involve substantial expenditure before a product receives approval for commercial use.

Clinical trial outcomes, manufacturing requirements and regulatory decisions can influence development timelines.

The company is therefore focusing its resources on selected programmes while reviewing expenditure across its broader portfolio.

Its research activities remain important to replacing revenue from products facing generic competition and supporting future therapeutic development.

Operating Cash Flow Reaches USD 3.5 Billion

Despite the statutory loss, CSL generated approximately USD 3.5 billion in cash flow from operations during FY26.

This represented a decline of approximately 1% compared with the previous financial year.

The difference between reported profitability and operating cash generation was partly attributable to non-cash impairment charges.

Asset impairments reduce accounting profit but do not necessarily involve a corresponding cash outflow during the reporting period.

Operating cash flow therefore provides an additional measure of CSL's financial capacity.

The company continues using cash generated from its businesses to fund manufacturing investment, research and development, financing obligations and Shareholder distributions.

At 30 June 2026, CSL reported net assets of approximately USD 16.3 billion.

Its Leverage Ratio stood at approximately 1.8 times, measured as net Debt relative to EBITDA under the company's adjusted definition.

The company continues managing financial resources while implementing its transformation programme.

However, cash generation will remain influenced by product revenue, operating expenses, Working Capital and investment requirements.

Dividend Maintained Despite Statutory Loss

CSL maintained its total FY26 Dividend at USD 2.92 per share, unchanged from FY25.

The annual distribution included a final dividend of USD 1.62 per share.

The final dividend was paid on 2 October 2026.

The unchanged payment reflected the company's assessment of underlying earnings, cash generation and financial resources.

During FY26, CSL also completed an AUD 1 billion on-market share buy-back programme.

The company subsequently announced an additional AUD 1.1 billion buy-back programme.

These capital management activities form part of its approach to allocating available financial resources.

However, future dividends and other capital management decisions will depend on profitability, investment requirements, financing obligations and the board's assessment of the company's financial position.

Deborah Waterhouse Appointed as CSL's Next Chief Executive Officer

CSL announced a significant leadership transition during 2026.

Dr Paul McKenzie retired as Chief Executive Officer and Managing Director in February 2026.

Following his departure, Gordon Naylor was appointed interim Chief Executive Officer.

Naylor previously held senior leadership positions within CSL, including Chief Financial Officer and President of CSL Seqirus.

On 21 October 2026, CSL announced the appointment of Deborah Waterhouse as its next Chief Executive Officer and Managing Director.

Waterhouse is scheduled to commence the role on 1 February 2027.

She brings more than 25 years of experience across the global pharmaceutical industry.

Her previous responsibilities include leadership of ViiV Healthcare and senior positions within GSK.

She has experience across specialty pharmaceuticals, vaccines and international commercial operations.

The appointment comes as CSL continues restructuring its business and addressing changing market conditions.

The new leadership team will be responsible for progressing the transformation programme, managing commercial priorities and overseeing the company's research and manufacturing investments.

The transition also coincides with planned changes to CSL's board leadership during 2027.

FY27 Guidance Indicates a Return to Underlying Earnings Growth

CSL has provided FY27 guidance for group revenue broadly in line with FY26.

The outlook is based on FY26 exchange rates.

The company expects underlying net profit after tax to increase by approximately 5% in constant currency terms.

The forecast reflects anticipated growth in CSL Behring and CSL Seqirus, partly offset by lower revenue from CSL Vifor.

CSL Behring is expected to record mid-single-digit revenue growth.

Within the division, immunoglobulin sales are forecast to increase at a mid-to-high single-digit rate.

CSL Seqirus is expected to generate low-single-digit revenue growth as seasonal influenza vaccine demand develops.

However, CSL Vifor revenue is expected to decline by approximately 25%.

The reduction reflects generic competition affecting iron products, reimbursement changes involving VELPHORO and regulatory developments associated with TAVNEOS.

The company reaffirmed its FY27 guidance during its Annual General Meeting on 27 October 2026.

The outlook incorporates management's expectations for product demand, operational efficiency and the financial effects of its restructuring programme.

Key Risks and Operational Considerations

CSL's financial performance remains exposed to competition, regulatory developments and changes in healthcare reimbursement arrangements.

Within CSL Behring, immunoglobulin revenue represents an important earnings contributor.

Competition from other plasma-derived therapies and alternative treatments could influence future product demand.

Changes in inventory arrangements and reimbursement policies may also affect sales.

CSL Vifor faces pressure from generic competition and regulatory developments involving selected products.

The company expects a substantial decline in divisional revenue during FY27, making the eventual financial impact an important consideration.

CSL Seqirus remains exposed to changes in influenza vaccination rates and public health policies.

Lower immunisation demand could affect product sales and manufacturing utilisation.

The company's impairment charges also highlight risks associated with changes in expected future cash flows and asset values.

Additional changes in commercial assumptions could result in further accounting adjustments.

Manufacturing operations involve regulatory compliance, production quality and Supply chain requirements.

The transformation programme also carries execution risks because restructuring and cost reduction initiatives must be implemented without disrupting product availability.

The leadership transition scheduled for February 2027 introduces an additional period of organisational change.

What Lies Ahead for CSL Limited in FY27?

CSL enters FY27 with a focus on improving underlying earnings, completing operational transformation initiatives and managing changing commercial conditions across its three major businesses.

The company expects group revenue to remain broadly consistent with FY26 while underlying net profit after tax increases by approximately 5%.

CSL Behring is expected to provide an important earnings contribution through mid-single-digit revenue growth and improved immunoglobulin sales.

The company continues investing in plasma manufacturing efficiency and expanding its therapeutic portfolio.

CSL Seqirus is expected to record low-single-digit revenue growth, although influenza vaccination trends remain an important factor.

Meanwhile, CSL Vifor faces a projected revenue decline of approximately 25% because of generic competition and regulatory changes.

Management is also progressing cost savings, targeted commercial investment and manufacturing productivity initiatives.

Deborah Waterhouse is scheduled to become Chief Executive Officer on 1 February 2027, marking the next stage of CSL's leadership transition.

The company's FY27 half-year results, expected in February 2027, will provide further information regarding immunoglobulin sales, Vifor revenue trends, Seqirus performance and the contribution from transformation initiatives.

CSL's ability to return to underlying earnings growth will depend on commercial execution, cost management and the performance of its established and newer therapies.

Frequently Asked Questions (FAQs)